A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

NCT04023994 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimers Disease

Interventions

DRUG: RO7126209
DRUG: Placebo

Sponsor

Hoffmann-La Roche